Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Novo Nordisk To File IcoSema (Insulin Icodec/Semaglutide Combo) Ex US

Aug 13, 2024

A representative from Novo Nordisk has recently announced that the company is planning to submit regulatory approval applications for its insulin icodec and semaglutide combination (IcoSema) in jurisdictions outside the US.  The decision to file the applications reportedly follows completion of the Phase III COMBINE-1 study in Q2 2024 which demonstrated that the combination achieved its primary endpoint of superior blood sugar control after 52 weeks versus insulin icodec alone.

Novo Nordisk will not be seeking regulatory approval of IcoSema in the US at this stage following the issue of a Complete Response Letter (CRL) by the US FDA on 10 July 2024 regarding insulin icodec for diabetes mellitus.

Novo Nordisk’s insulin icodec was approved as Awiqli® in certain jurisdictions including Europe, Switzerland and Canada, Japan and Australia, and endorsed in China.